Mizuho Securities USA LLC Has $5.34 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Key Points

• Mizuho Securities USA LLC has reduced its stake in Regeneron Pharmaceuticals by 15.6%, bringing its holdings to 8,424 shares worth approximately $5.34 million.
• Analysts have mixed ratings on Regeneron, with a consensus rating of "Moderate Buy" and an average price target of $841.30.
• The company announced a quarterly dividend of $0.88 per share, reflecting an annualized yield of 0.6% and a dividend payout ratio of 8.87%.

Mizuho Securities USA LLC lowered its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 15.6% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 8,424 shares of the biopharmaceutical company's stock after selling 1,553 shares during the quarter. Mizuho Securities USA LLC's holdings in Regeneron Pharmaceuticals were worth $5,343,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in the business. Benjamin Edwards Inc. increased its position in Regeneron Pharmaceuticals by 18.6% in the 1st quarter. Benjamin Edwards Inc. now owns 1,955 shares of the biopharmaceutical company's stock valued at $1,240,000 after acquiring an additional 307 shares during the period. Covestor Ltd increased its holdings in Regeneron Pharmaceuticals by 68.8% in the first quarter. Covestor Ltd now owns 314 shares of the biopharmaceutical company's stock valued at $200,000 after purchasing an additional 128 shares during the period. Frank Rimerman Advisors LLC raised its position in Regeneron Pharmaceuticals by 74.4% during the 1st quarter. Frank Rimerman Advisors LLC now owns 914 shares of the biopharmaceutical company's stock worth $580,000 after purchasing an additional 390 shares during the last quarter. Koss Olinger Consulting LLC bought a new position in Regeneron Pharmaceuticals during the 1st quarter worth $235,000. Finally, Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Regeneron Pharmaceuticals by 105.2% in the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,917 shares of the biopharmaceutical company's stock valued at $1,216,000 after buying an additional 983 shares during the last quarter. Institutional investors own 83.31% of the company's stock.

Analysts Set New Price Targets

REGN has been the subject of a number of analyst reports. Cantor Fitzgerald assumed coverage on Regeneron Pharmaceuticals in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $695.00 price objective for the company. Canaccord Genuity Group restated a "buy" rating and set a $850.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, July 23rd. Wells Fargo & Company lowered shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 price objective on the stock. in a research note on Friday, August 1st. Truist Financial decreased their price objective on shares of Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating for the company in a research report on Wednesday, April 30th. Finally, Robert W. Baird dropped their target price on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating on the stock in a report on Friday, April 25th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have given a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $841.30.

Regeneron Pharmaceuticals Stock Up 0.6%

Shares of NASDAQ:REGN opened at $563.00 on Friday. The stock has a market cap of $60.78 billion, a price-to-earnings ratio of 14.19, a PEG ratio of 1.91 and a beta of 0.33. The business's 50 day moving average is $536.80 and its 200 day moving average is $599.19. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $1,211.20. The company has a quick ratio of 4.73, a current ratio of 4.60 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm had revenue of $3,675,600 billion for the quarter, compared to analysts' expectations of $3.30 billion. During the same quarter last year, the firm earned $11.56 EPS. The company's quarterly revenue was up 3.6% compared to the same quarter last year. On average, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.